Tema Oncology ETF (NASDAQ:CANC) Short Interest Update

Tema Oncology ETF (NASDAQ:CANC) saw a significant decrease in short interest in October. As of October 15th, there was short interest totalling 1,600 shares, a decrease of 30.4% from the September 30th total of 2,300 shares. Based on an average daily volume of 3,800 shares, the days-to-cover ratio is presently 0.4 days.

Tema Oncology ETF Price Performance

Shares of NASDAQ:CANC traded up $0.05 on Tuesday, reaching $27.93. 3,603 shares of the company traded hands, compared to its average volume of 6,994. The stock has a market capitalization of $48.60 million, a PE ratio of 26.86 and a beta of 1.11. The company’s 50 day moving average is $28.69 and its 200-day moving average is $27.96. Tema Oncology ETF has a fifty-two week low of $21.47 and a fifty-two week high of $30.11.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans acquired a new stake in shares of Tema Oncology ETF (NASDAQ:CANC) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned approximately 19.01% of Tema Oncology ETF as of its most recent filing with the Securities & Exchange Commission.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.